Completed PHASE2 INTERVENTIONAL 3-arm NCT00515411

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Sponsor: City of Hope National Medical Center

Conditions Gastric Cancer Gastroesophageal Junction Adenocarcinoma

Interventions Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen Docetaxel, Leucovorin, Fluorouracil, Cisplatin Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab

Updated 11 times since 2017 Last updated: Nov 25, 2019 Started: Oct 23, 2006 Primary completion: Oct 26, 2018 Completion: Oct 26, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00515411, this PHASE2 trial focuses on Gastric Cancer and Gastroesophageal Junction Adenocarcinoma and remains completed. Sponsored by City of Hope National Medical Center, it has been updated 11 times since 2006, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 6 earlier versions

Jan 2020 — Jan 2021 [monthly]

Completed PHASE2
Nov 2018 — Jan 2020 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Aug 2018 — Nov 2018 [monthly]

Active Not Recruiting PHASE2
Jun 2018 — Aug 2018 [monthly]

Active Not Recruiting PHASE2
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

City of Hope National Medical Center
Long Island Jewish Medical Center
Medical College of Wisconsin
Memorial Cancer Institute, Florida
Memorial Sloan Kettering Cancer Center
Nebraska Cancer Specialists Methodist Estabrook Cancer Center
Piedmont Hospital Research Institute
Queens Health Network
Roche-Genentech
Sanofi
University of Pittsburgh
Weill Medical College of Cornell University

Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Basking Ridge, United States , Cleveland, United States , Commack, United States , Duarte, United States , Jamaica, United States , Milwaukee, United States , New Hyde Park, United States , New York, United States , Omaha, United States and 4 more locations